This study is testing new combinations of immunotherapy drugs for people with certain types of head and neck cancer. Immunotherapy helps the body's immune system fight cancer. The study is for people whose cancer has returned or spread (recurrent/metastatic) and is PD-L1 positive, meaning the cancer has a specific protein that can be targeted by these drugs.
To join, participants must have a confirmed diagnosis of this type of cancer and not have had certain previous treatments. Participants will provide a sample of their tumor for testing. If the cancer started in the oropharynx, HPV testing is needed. The study excludes people who have received similar treatments before, have certain other cancers, or have conditions like serious bleeding or autoimmune diseases.
- Study length: Participants will be monitored for changes in their cancer and any side effects.
- Visits needed: Regular visits for treatment and monitoring are required.
- Risks: Potential side effects from treatment, but safety is a key focus.